HIV vaccine research must consider various immune responses

April 3, 2014, NIH/National Institute of Allergy and Infectious Diseases

Last year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, held a scientific meeting to examine why certain investigational HIV vaccines may have increased susceptibility to HIV infection. In a new perspectives article appearing in the journal Science, HIV research leaders from NIAID (Anthony S. Fauci, M.D., and Carl W. Dieffenbach, Ph.D.) and its grantees at Emory University (Eric Hunter, Ph.D.) and the University of California, San Francisco (Susan Buchbinder, M.D.), summarize the findings and considerations for future HIV vaccine research.

Between 2005 and 2013, investigational HIV vaccines based on recombinant adenovirus type 5 (rAd5), a weakened type of cold virus designed to deliver genetic material, were tested in three clinical trials. Two of those studies, known as Step and Phambili, involved the same experimental . Both studies showed no efficacy against acquisition of HIV infection; however, they suggested an increased risk of HIV acquisition among vaccinated male study participants. Based on subsequent analyses, the authors hypothesize that the rAd5-based vaccines tested may have heightened susceptibility to HIV infection by activating for sustained periods CD4+ T-cells, the key target for HIV, while producing ineffective or limited protective effects against HIV.

Given the lack of efficacy demonstrated by rAd-5 based HIV candidates and the potential increased risk for HIV acquisition, further development of HIV vaccines using rAd-5 vectors are inappropriate, the authors write. Researchers who want to pursue HIV vaccines using different adenoviruses or other vaccine delivery systems should perform a risk-benefit analysis that weighs the balance between the potential anti-HIV vaccine responses and protective benefit of the vaccine against the vaccine-induced risk of increased HIV acquisition due to heightened CD4+ T-cell activation.

Moving forward, the HIV vaccine research field would benefit by clarifying the role vaccine vectors play in overall HIV vaccine effectiveness, identifying biomarkers in nonhuman primates that indicate increased risk for HIV acquisition, and developing a better understanding of mucosal immune system responses to HIV vaccination, according to the authors.

Explore further: Past HIV vaccine trials reveal new path to success

More information: AS Fauci et al. Immune Activation with HIV Vaccines. Science. DOI: 10.1126/science.1250672

Related Stories

Past HIV vaccine trials reveal new path to success

March 19, 2014
A multi-national research team led by Duke Medicine scientists has identified a subclass of antibodies associated with an effective immune response to an HIV vaccine.

Durable end to AIDS will require HIV vaccine development

February 5, 2014
Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately ...

Adaptive trial designs could accelerate HIV vaccine development

April 20, 2011
In the past 12 years, four large-scale efficacy trials of HIV vaccines have been conducted in various populations. Results from the most recent trial—the RV144 trial in Thailand, which found a 31 percent reduction ...

Study of antibody evolution charts course toward HIV vaccine

March 2, 2014
In an advance for HIV vaccine research, a scientific team has discovered how the immune system makes a powerful antibody that blocks HIV infection of cells by targeting a site on the virus called V1V2. Many researchers believe ...

Researchers discuss challenges to developing broadly protective HIV vaccines

September 7, 2011
The human body can produce powerful antibodies that shield cells in the laboratory against infection by an array of HIV strains. In people, however, recent research shows that these broadly neutralizing antibodies are not ...

HIV vaccines elicit immune response in infants

October 8, 2013
A new analysis of two HIV vaccine trials that involved pediatric patients shows that the investigational vaccines stimulated a critical immune response in infants born to HIV-infected mothers, researchers at Duke Medicine ...

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.